About Matthew Bryant

Matt Bryant has been a visionary and driving force around transforming the patient experience in clinical trials for nearly a decade. His background in Computer Science and Business has supported nearly two decades of clinical development expertise to deliver numerous products and applications serving patients, investigators, and biopharma enterprises.

In addition to holding a variety of roles in clinical development, innovation, technology and design at Eli Lilly, Amgen and currently, Gilead Sciences, Matt has created new ventures such as being a founding member of the direct-to-patient startup, Lightship backed by Khosla Ventures, McKesson Ventures, Define Ventures, Brook Byers and Marc Benioff.

Matt has lived and worked in the largest pharmaceutical markets globally, spending extensive time with patients, caregivers, investigators and regulatory agencies to listen and act on the necessary infrastructure to evolve how clinical programs are designed and delivered.